| Drug Name | pazopanib |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Potential Risk of Tumor Lysis Syndrome Associated with the Use Pazopanib |
| other |
Safety Communication Pazopanib 2020 |